Novartis Purchase Of Bristol OTCs Has Excedrin Written All Over It
This article was originally published in The Tan Sheet
Novartis will enter the U.S. over-the-counter analgesics market with Excedrin as part of the purchase of Bristol-Myers Squibb's OTC portfolio
You may also be interested in...
Listerine anticavity: New Listerine Tooth Defense contains fluoride to "strengthen tooth enamel and protect against caries," McNeil announces. The mouthwash helps decrease caries at the root surface and enamel crown, inhibits the demineralization of enamel and enhances mineralization, McNeil claims. Available in Mint-Shield flavor, the product will carry suggested retail prices of $3.29 to $5.89. Although Tooth Defense kills germs that cause oral malodor, it is "not intended to help prevent or reduce plaque and gingivitis," the company notes. Johnson & Johnson picked up the brand after it closed its Pfizer Consumer Healthcare acquisition in December for $16.6 bil. in cash (1"The Tan Sheet" Jan. 1, 2007, In Brief). J&J divested its ACT fluoride mouth rinse to Chattem Jan. 2 in conjunction with the Pfizer acquisition (2"The Tan Sheet" Feb. 19, 2007, p. 10)...
Novartis Consumer Health showed "strong performance" in 2006 with full year net sales of $7.53 billion, according to earnings results announced during a fourth-quarter and year-end call Jan. 18
Over-the-counter and generic drugs will benefit "disproportionately" compared with prescription drugs in emerging global markets, according to Novartis Head of Corporate Mergers & Acquisitions Nayan Gregory Parekh, PhD